

State of Oklahoma **Oklahoma Health Care Authority Factor Replacement Products Prior Authorization Form**

Member Name:	Date of Birth:	Member ID#:
		Pharmacy Fax:
Pharmacy Name: Pharmacist Name:		
Prescriber NPI: Prescriber Name:		
		Prescriber Fax:
Fill Date:	<u> </u>	
	Clinical Information	on
1 Diagnosis (ICD 10)		
Plagnosis (ICD-10): Factor Replacement Pro-	duct:	No:
3. NDCs to be potentially us	sed throughout year (to be comp	leted by the dispensing pharmacy):
		- -
4 Fetimete tetal unite te be		
4. Estimate total units to be	an extended half-life factor prod	uct or Obizur® a patient-specific clinically
significant reason why cu	irrent factor product cannot be u	sed (or Feiba [®] and NovoSeven [®] if request-
ing Obizur®) must be pro	vided:	(
		
6. Has a half-life study beer	n performed? Yes No	Date(s) performed:
For extended half-life fac	tor products was there a signification	ant benefit seen in half-life? Yes No:
□ I recommend this nationt	he followed by an OHCA Care N	Aspagement Nurse
i recommend this patient	be followed by an OHCA Care N	wanagement Nurse.
Prescriber Signature:		Date:
Pharmacist Signature:		Date:
Please do not send in chart	notes. Specific information/docu	imentation will be requested if necessary.
	in full will result in processing d	

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit Fax: 1-800-224-4014

Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.